EU Commission approved Roche’s Tecentriq in combination with Avastin for the treatment of people with liver cancer
The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. “Tecentriq in combination with Avastin is the first treatment to be approved in over a decade
Latest comments